NFKB1 and bacterial pneumonia: QFY therapeutic effects appeared to be associated with both repair of disordered intestinal flora through restoration of basal SCFAs levels to normal levels (in uninfected mice) and inhibition of NF-κB-NLRP3 pathway activity, which together alleviated lung injury induced by bacterial pneumonia.